Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore, 117596, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), Centre for Life Sciences, National University of Singapore, 28 Medical Drive, Singapore, 117456, Singapore.
UES, Inc., Dayton, OH, 45432, United States; Air Force Research Laboratory, 711th Human Performance Wing, Wright-Patterson Air Force Base, OH, 45433, United States.
Curr Opin Biotechnol. 2020 Oct;65:171-179. doi: 10.1016/j.copbio.2020.02.016. Epub 2020 Apr 15.
Engineered probiotics are the next generation of live biotherapeutics that have been genetically modified to target specific diseases. With the advancements in synthetic biology, the engineering of probiotics has become increasingly sophisticated which has led to the development of therapies for treating cancer, infection, metabolic disorders and inflammation, as well as for diagnosing and preventing them. Herein, we review some of the recent examples of probiotics which have been engineered to target such diseases. Although there are numerous examples of engineered probiotics showing efficacy in animal models, there are no approved products on the market with very few in clinical trials. Therefore, we also discuss a set of features that may be incorporated into engineered probiotics to aid in clinical translation and ultimately, realizing the potential of these biotherapeutics.
工程益生菌是下一代经过基因改造以针对特定疾病的活体生物疗法。随着合成生物学的进步，益生菌的工程设计变得越来越复杂，从而为治疗癌症、感染、代谢紊乱和炎症以及诊断和预防这些疾病开发了疗法。在此，我们回顾了一些经过工程设计以针对此类疾病的益生菌的最新实例。尽管有许多经过基因改造的益生菌在动物模型中显示出疗效的例子，但市场上没有批准的产品，临床试验也很少。因此，我们还讨论了一组可能被纳入工程益生菌中的特征，以帮助其进行临床转化，并最终实现这些生物疗法的潜力。
